61439-60-9

Upstream product

• 61439-59-6 2-(4-benzyloxyphenyl)ethanol 
• 124-63-0 methanesulfonyl chloride 
• 100-39-0 benzyl bromide 
• 501-94-0 p-hydroxyphenethyl alcohol 
• 17138-28-2 (4-hydroxy-phenyl)-acetic acid ethyl ester 

Downstream Products

• 80199-93-5 1-[4-(benzyloxy)phenethyl]-1H-imidazole 
• 817642-83-4 S-(2-[4-(benzyloxy)phenyl]ethyl) ethanethioate 
• 733047-95-5 11-[2-(4-benzyloxyphenyl)ethyl]-11H-benzo[f]pyrido[3,2-c][1,2,5]oxathiazepine 5,5-dioxide 
• 80200-06-2 4-[2-(1-imidazolyl)ethyl]phenol 
• 163930-30-1 2-<4-(Benzyloxy)phenyl>ethyl iodide 
• 342024-03-7 ethyl (1-[2-(4-benzyloxyphenyl)ethyl]-3-phenyl-1H-pyrazol-4-yl)acetate 
• 61439-62-1 p-[(p-Benzyloxyphenethyl)amino]benzoic Acid 
• 80200-08-4 4-[2-(1H-1,2,4-triazol-1-yl)ethyl]phenol 
• 80200-07-3 4-[2-(1-pyrazolyl)ethyl]phenol 
• 98088-86-9 1-<2-<4-<2-<4<<1-<(4-fluorophenyl)methyl>-1H-benzimidazol-2-yl>amino>-1-piperidinyl>ethyl>phenoxy>acetyl>piperidine 
• 75971-25-4 {4-[2-{4-[1-(4-fluorophenylmethyl)-1H-benzimidazol-2-ylamino]-1-piperidinyl}ethyl]phenoxy}acetonitrile 
• 75971-21-0 {1-[2-(4-Allyloxy-phenyl)-ethyl]-piperidin-4-yl}-[1-(4-fluoro-benzyl)-1H-benzoimidazol-2-yl]-amine 
• 73736-60-4 4-<2-<4-<<1-<(4-fluorophenyl)methyl>-1H-benzimidazol-2-yl>amino>-1-piperidinyl>ethyl>phenyl phenylmethyl carbonate 
• 73736-58-0 4-<2-<4-<<1-<(4-fluorophenyl)methyl>-1H-benzimidazol-2-yl>amino>-1-piperidinyl>ethyl>phenyl 4-methoxybenzoate 

Relevant academic research and scientific papers

In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: Trends across multiple chemical series

Structure-activity relationships (SAR) were analyzed within a library of diverse yet simple compounds prepared as histamine H3 antagonists. The libraries were constructed with a variety of low molecular weight pyrrolidines, selected from (R)-2-methylpyrrolidine, (S)-2-methylpyrrolidine, and pyrrolidine.

Novel benzopyridothiadiazepines as potential active antitumor agents

The synthesis of novel thiadiazepine derivatives, that could be considered as constraint analogues of E-7010, are reported. These molecules were evaluated for their antiproliferative activity toward the murine L1210 leukemia cell line. Flow cytometric studies performed on L1210 cells with the most cytotoxic compounds showed an accumulation of the cells in the G2/M phases of the cell cycle with a significant percentage of tetraploid cells (8N DNA content). Submicromolar cytotoxicities were observed with compounds 2b, 4b, 4e, 4g, and 4i. Two of them, compounds 2b and 4b, were found to be potent inhibitors of tubulin polymerization with IC50 of respectively 3.8 and 2.4 μM compared to 2.4 μM for desoxypodophyllotoxin. A 4-methoxyphenylethyl substitution on the pyridinyl nitrogen of the benzopyridothiadiazepine was found to be essential for the antiproliferative activity. The in vitro activities of compounds 2b and 4b make benzopyridothiadiazepine dioxides a promising new class of tubulin binders which warrant further in vivo evaluation.

AMINOPROPANOL DERIVATIVES

Compounds of formula (I): wherein R1, R2, n and m are as defined in the specification, processes for their production, their uses and pharmaceutical compositions containing them.

5-MEMBERED N-HETEROCYCLIC COMPOUNDS WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY

Use of a compound of the formula: wherein R represents a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; X represents a bond, an oxygen atom, a sulfur atom, or a group of the formula: -CO-, -CS-, -CR(OR)- or -NR- wherein each of R and R represents a hydrogen atom or a hydrocarbon group which may be substituted, R represents a hydrogen atom or a protective group for a hydroxyl group; m represents an integer of 0 to 3; Y represents an oxygen atom, a sulfur atom, or a group of the formula: -SO-, -SO2-, -NR-, -CONR- or -NRCO- wherein R represents a hydrogen atom or a hydrocarbon group which may be substituted; ring A represents an aromatic ring which may further have 1 to 3 substituents; n represents an integer of 1 to 8; ring B represents a nitrogen-containing 5-membered hetero ring which may further be substituted by an alkyl group; X represents a bond, an oxygen atom, a sulfur atom, or a group of the formula: -SO-, -SO2-, -O-SO2- or -NR- wherein R represents a hydrogen atom or a hydrocarbon group which may be substituted; R represents a hydrogen atom, a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; W represents a bond or a divalent hydrocarbon residue having 1 to 20 carbon atoms; R represents a group of the formula: -OR (R represents a hydrogen atom or a hydrocarbon group which may be substituted) or -NRR (each of R and R, whether identical or not, represents a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, or an acyl group which may be substituted; R and R may bind together to form a ring); or a salt thereof, for the manufacture of a pharmaceutical preparation for preventing or treating syndrome X.

THERAPEUTIC AGENTS

Substituted 3-phenylpropionic acid derivatives, processes for preparing such compounds, their utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, methods for their therapeutic use and pharmaceutical compositions containing them.

4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists

PCT No. PCT/US96/20872 Sec. 371 Date Sep. 16, 1998 Sec. 102(e) Date Sep. 16, 1998 PCT Filed Dec. 20, 1996 PCT Pub. No. WO97/23216 PCT Pub. Date Jul. 3, 1997Novel 4-substituted piperidine analogs, pharmaceutical compositions containing the same and the method of using 4-substituted piperidine analogs are selective active antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes for treating conditions such as stroke, cerebral ischemia, central nervous system trauma, hypoglycemia, psychosis, anxiety, migraine headaches, glaucoma, CMV retinitis, aminoglycoside antibiotics-induced hearing loss, convulsions, chronic pain, opioid tolerance or withdrawal, urinary incontinence or neurodegenerative disorders, such as lathyrism, Alzheimer's Disease, Parkinsonism and Huntington's Disease are described.

SUBSTITUTED PHENOXY-AMINOPROPANOL DERIVATIVES

Phenoxy-aminopropanol derivatives of the formula STR1 wherein R is lower alkyl, X is oxygen or sulfur, n is the integer zero or 1, Y is methylene, ethylene or propylene or, when n is zero, Y can also be a group of the formula EQU1 , wherein the double-bond is trans and the carbon atom marked with an asterisk is linked to Z, and Z is a 5-membered aromatic heterocyclic ring which contains one or more nitrogen atoms as the sole hetero atom (s), said heterocyclic ring is linked to Y via a nitrogen atom, and may be substituted by halogen, lower alkyl, lower alkoxy, aryl, cyano or carboxamido, or on adjacent carbon atoms by a group of the formula STR2 and pharmaceutically acceptable acid addition salts thereof are described. A process for the preparation of the compound of formula I and pharmaceutical preparations containing them are also described. The aforementioned compounds and salts possess β-adrenergic blocking activity and antihypertensive activity.

Antilipidemic para-[aryl(alkyl or alkenyl)amino]-benzoic acid derivatives

Novel para-[aryl(alkyl or alkenyl)amino]benzoic acids, esters, pharmaceutically acceptable salts and pharmaceutical compositions thereof and a method of lowering serum lipid levels in mammals therewith.